Spermosens are active in medical technology. The company specializes in the development of medical devices. The product portfolio is broad and includes products for male infertility and individually tailored fertility treatments. Research and development is conducted via its own technological platform that analyzes sperm quality, which is further used for medical data and potential fertilization. The largest operations are in the Nordic market.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Avanza Pension | 12,75 | 12,75 | 2023-06-28 |
| Magnus Brandt | 4,67 | 4,67 | 2023-09-21 |
| Kushagr Punyani | 3,98 | 3,98 | 2023-06-28 |
| Andreas Ward | 2,85 | 2,85 | 2023-06-28 |
| Nordnet Pensionsförsäkring | 2,63 | 2,63 | 2023-06-28 |
| Sven Rasmusson | 2,26 | 2,26 | 2023-06-28 |
| Mohamad Takwa | 1,70 | 1,70 | 2023-06-28 |
| Gabriella Jarnelid Pettersson | 1,14 | 1,14 | 2023-06-28 |
| Rune Löderup | 1,02 | 1,02 | 2023-06-28 |
| Søren Melsing Frederiksen | 0,96 | 0,96 | 2023-02-01 |
2023-10-13 Delårsrapport 2023-Q3
2024-02-09 Bokslutskommuniké 2023